AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16131287 — intervention group
Group type: COMPARATOR
Intervention: Sweet almond oil (placebo/control)
Number of subjects: 10
Study 12395437 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal protection with mannitol (0.3 g/kg) before aortic cross-clamping (ACC) and furosemide (20-40 mg) or dopamine (1-3 micrograms/kg/min) until the end of surgery.
Number of subjects: 80
Study 12395437 — intervention group
Group type: COMPARATOR
Intervention: No renal protection (group A).
Number of subjects: 80
Study 10091344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.2%)
Number of subjects: 125
Study 10091344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg/12 h)
Number of subjects: 125
Study 10091344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.5%)
Number of subjects: 125
Study 10091344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus 0.2% topical solution
Number of subjects: 125
Study 10091344 — intervention group
Group type: COMPARATOR
Intervention: Topical polymyxin and neomycin
Number of subjects: 125
Study 7748985 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg ideal weight/h)
Number of subjects: 14
Study 7748985 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14
Study 7748985 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 14
Study 2148224 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 1 mg i.v. (5 min)
Number of subjects: 10
Study 2148224 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 5 mg solution
Number of subjects: 10
Study 2148224 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 5 mg tablet
Number of subjects: 10
Study 2148224 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 10 mg sustained release
Number of subjects: 10
Study 2148224 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6809321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 45
Study 6809321 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 45
Study 31732133 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus conventional treatment
Number of subjects: 245
Study 31732133 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 245
Study 30963552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose)
Number of subjects: 116
Study 30963552 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate)
Number of subjects: 116
Study 28583700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 240
Study 28583700 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 240
Study 26022239 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 135
Study 26022239 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy and ASCT
Number of subjects: 135
Study 26022239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high-dose cytarabine)
Number of subjects: 135
Study 24224992 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary otoscopy training including didactic otoscopy lectures and clinical training using manikin ears
Number of subjects: 32
Study 24224992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary training initially)
Number of subjects: 32
Study 24224992 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental and control groups
Number of subjects: 32
Study 21222604 — intervention group
Group type: EXPERIMENTAL
Intervention: EHT0202 (40 or 80 mg bid)
Number of subjects: 159
Study 21222604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 21222604 — intervention group
Group type: EXPERIMENTAL
Intervention: EHT0202
Number of subjects: 159
Study 19573497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 30 mg/d
Number of subjects: 24
Study 19573497 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 300 mg/d
Number of subjects: 24
Study 17550958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg)
Number of subjects: 10
Study 17550958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17169762 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 51
Study 17169762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 51
Study 15298795 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 51
Study 15298795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 51
Study 15298795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control intervention (training of child care staff about transmission of infection and handwashing)
Number of subjects: 311
Study 10742314 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 311
Study 10742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control intervention (with high compliance to handwashing)
Number of subjects: 311
Study 9398875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid plus amoxicillin, 1 gm tid
Number of subjects: 262
Study 9398875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg tid plus amoxicillin, 1 gm tid
Number of subjects: 262
Study 9398875 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole, 30 mg tid alone
Number of subjects: 262
Study 9398875 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, 1 gm tid alone
Number of subjects: 262
Study 9398875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid plus amoxicillin
Number of subjects: 262
Study 9398875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg tid plus amoxicillin
Number of subjects: 262
Study 1572111 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1000 mg/d)
Number of subjects: 20
Study 1572111 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (2000 mg/d)
Number of subjects: 20
Study 1572111 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (0.5 mg/kg intravenously)
Number of subjects: 20
Study 4048886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (0.1 mg/kg/min)
Number of subjects: 25
Study 4048886 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25
Study 31266353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 31266353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 31266353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 0
Study 31266353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28207540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 501
Study 28207540 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 501
Study 28207540 — intervention group
Group type: COMPARATOR
Intervention: 3.75 mg enantone
Number of subjects: 501
Study 26390335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 26390335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Number of subjects: 0
Study 26390335 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 0
Study 23849965 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge heart rate 60-69 bpm
Number of subjects: 2029
Study 23849965 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge heart rate 70-79 bpm
Number of subjects: 2029
Study 23849965 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge heart rate 80-89 bpm
Number of subjects: 2029
Study 23849965 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge heart rate >90 bpm
Number of subjects: 2029
Study 23849965 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge heart rate <60 bpm
Number of subjects: 2029
Study 21730029 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise protein feeding (PTN: 0.4, 1.2, 0.2 g/kg protein, carbohydrate, and fat respectively)
Number of subjects: 8
Study 21730029 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise protein feeding (PTN)
Number of subjects: 8
Study 21730029 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate and fat (CON: 1.6, 0.2 g/kg)
Number of subjects: 8
Study 17895513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 25
Study 17895513 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 25
Study 17349094 — intervention group
Group type: COMPARATOR
Intervention: Regular Weight Watchers POINTS programme
Number of subjects: 96
Study 17349094 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised programme encouraging low GI foods
Number of subjects: 96
Study 14625735 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in three other simulators with different visual-spatial components
Number of subjects: 28
Study 14625735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training in other simulators)
Number of subjects: 28
Study 11146518 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone
Number of subjects: 0
Study 11146518 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 0
Study 9135193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 60
Study 9135193 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal saline placebo
Number of subjects: 60
Study 8176554 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 18
Study 8176554 — intervention group
Group type: COMPARATOR
Intervention: Voluntary coughing
Number of subjects: 18
Study 8176554 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 18
Study 3299495 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexphenidyl (Artane)
Number of subjects: 20
Study 3299495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30102667 — intervention group
Group type: EXPERIMENTAL
Intervention: V-pattern injection (group 1)
Number of subjects: 45
Study 30102667 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle horizontal pattern injection (group 2)
Number of subjects: 45
Study 30102667 — intervention group
Group type: EXPERIMENTAL
Intervention: High horizontal pattern injection (group 3)
Number of subjects: 45
Study 28219752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 28219752 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness period (Control)
Number of subjects: 0
Study 28219752 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit knowledge acquisition before sleep
Number of subjects: 0
Study 26156077 — intervention group
Group type: EXPERIMENTAL
Intervention: High palmitate (HPA) diet
Number of subjects: 17
Study 26156077 — intervention group
Group type: COMPARATOR
Intervention: Low palmitate/high oleic acid (HOA) diet
Number of subjects: 17
Study 24140296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 0
Study 24140296 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 0
Study 20949623 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine
Number of subjects: 17622
Study 20949623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17622
Study 20949623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (vaccine and placebo)
Number of subjects: 17622
Study 18716740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifilac (probiotic)
Number of subjects: 80
Study 18716740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17288230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) with significant restriction of the number of cigarettes smoked per day
Number of subjects: 0
Study 15248628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 3 microg kg(‐1) min(‐1)
Number of subjects: 45
Study 15248628 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg(‐1) min(‐1)
Number of subjects: 45
Study 15248628 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg kg(‐1)
Number of subjects: 45
Study 10966884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods (various types including milk and yogurt)
Number of subjects: 57
Study 10966884 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger-evidence studies of dairy foods
Number of subjects: 57
Study 10966884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods in <30-y-olds
Number of subjects: 57
Study 10966884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods in 30-50-y-olds
Number of subjects: 57
Study 10966884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods in >50-y-olds
Number of subjects: 57
Study 8956395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-clonidine retrobulbar block (3-4 mL of 2% lidocaine with clonidine 2 micrograms/kg)
Number of subjects: 60
Study 8956395 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine retrobulbar block (3-4 mL of 2% lidocaine with 1 mL saline)
Number of subjects: 60
Study 1373231 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (125 micrograms/hour)
Number of subjects: 33
Study 1373231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3891900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure immune serum globulin (ISG)
Number of subjects: 802
Study 3891900 — intervention group
Group type: COMPARATOR
Intervention: No pre-exposure immune serum globulin (ISG)
Number of subjects: 802
Study 31647836 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily (BID) for fifteen days
Number of subjects: 14
Study 31647836 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin 300 mg once daily (QD) added on day six
Number of subjects: 14
Study 29702070 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 0
Study 29702070 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based rehabilitation
Number of subjects: 0
Study 27107307 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid Subortholene orthoses
Number of subjects: 9
Study 27107307 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft EVA orthoses
Number of subjects: 9
Study 24382410 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 50
Study 24382410 — intervention group
Group type: COMPARATOR
Intervention: Medical rate control
Number of subjects: 50
Study 22459124 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) approach
Number of subjects: 44
Study 22459124 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical approach
Number of subjects: 44
Study 20145562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) supplementation
Number of subjects: 15
Study 20145562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose 950 mg and glutamate 30 mg)
Number of subjects: 15
Study 19056532 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (0.8 mg/ml)
Number of subjects: 97
Study 19056532 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Infliximab)
Number of subjects: 97
Study 16837737 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 15 days plus serratiopeptidase 10 mg daily for 30 days
Number of subjects: 50
Study 16837737 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 50
Study 16837737 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment
Number of subjects: 50
Study 16837737 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 50
Study 14984226 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 1587
Study 14984226 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 1587
Study 14984226 — intervention group
Group type: EXPERIMENTAL
Intervention: zolmitriptan 2.5 mg
Number of subjects: 1587
Study 14984226 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1587
Study 10664830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (intravenous bolus 0.26 mg/kg followed by infusion of 0.65 mg/kg/hour)
Number of subjects: 22
Study 10664830 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study 9134412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal oxygen saturation monitoring (pulse oximeter)
Number of subjects: 0
Study 9134412 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8403806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose ingestion (75 g) in hypertensive patients
Number of subjects: 16
Study 8403806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose ingestion (75 g) with potassium chloride supplementation in hypertensive patients
Number of subjects: 16
Study 8403806 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose ingestion (75 g) in normotensive control subjects
Number of subjects: 16
Study 3782648 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 12
Study 3782648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention group without yoga postures
Number of subjects: 75
Study 30722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention group with yoga postures
Number of subjects: 75
Study 30722837 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 75
Study 26886370 — intervention group
Group type: EXPERIMENTAL
Intervention: Water protocol
Number of subjects: 14
Study 26886370 — intervention group
Group type: COMPARATOR
Intervention: Thickened liquids only
Number of subjects: 14
Study 24842558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W (with uptitration to 150 mg Q2W if LDL-C ≥70 mg/dL at Week 8)
Number of subjects: 800
Study 24842558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W throughout the treatment period (in HIGH FH)
Number of subjects: 800
Study 24842558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 22425218 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (NAs)
Number of subjects: 32144
Study 22425218 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (40 mg QD)
Number of subjects: 32144
Study 22425218 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 32144
Study 22425218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 32144
Study 20574636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (Pre‐post HIV counseling); N = 50
Number of subjects: 100
Study 20574636 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (Standard + Body Wise Intervention); N = 50
Number of subjects: 100
Study 18430172 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin
Number of subjects: 60
Study 18430172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroquinone
Number of subjects: 60
Study 18430172 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid peels alone (Control)
Number of subjects: 60
Study 15867404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat diet
Number of subjects: 120
Study 15867404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Plus diet
Number of subjects: 120
Study 15867404 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 120
Study 12651685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC, 1 M; n = 12)
Number of subjects: 24
Study 12651685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris-hydroxymethyl aminomethane (THAM, 3 M; n = 12)
Number of subjects: 24
Study 11804898 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary unenhanced helical CT (protocol B)
Number of subjects: 96
Study 11804898 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced radiography and sonography with helical CT in unclear cases (protocol C)
Number of subjects: 96
Study 11804898 — intervention group
Group type: COMPARATOR
Intervention: Combined sonography and radiography (protocol A)
Number of subjects: 96
Study 10416732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (individual daily sessions of 1 hour for up to 3 months)
Number of subjects: 0
Study 10416732 — intervention group
Group type: COMPARATOR
Intervention: Intensive occupational therapy (control group)
Number of subjects: 0
Study 7569830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement therapy plus norethisterone acetate 1 mg per day, oral, cyclically for 12 days monthly
Number of subjects: 112
Study 7569830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 112
Study 7569830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 112
Study 2341828 — intervention group
Group type: EXPERIMENTAL
Intervention: ESKIMO-3 (15 ml daily for 6 months)
Number of subjects: 33
Study 2341828 — intervention group
Group type: EXPERIMENTAL
Intervention: ESKIMO-3 (30 ml daily for 4 weeks)
Number of subjects: 33
Study 2341828 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 33
Study 7246688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided midtrimester amniocentesis
Number of subjects: 0